- Email: [email protected]
4503036 Process for producing a biochemical vaccine against salmonella infection
128
PATENT ABSTRACTS
preparative scale to provide homogeneous end product in excellent yield. In an embodiment of the process, human interferon is produced as a homogeneous protein.
4503039 COAGULANT PLASMA-PROTEIN SOLUTION Ronald Kotitschke, Wolfgang Stephan, Dreieich, Federal Republic Of Germany assigned to Biotest-Serum-lnstitut GmbH
4503036 PROCESS FOR PRODUCING BIOCHEMICAL VACCINE AGAINST SALMONELLA INFECTION
A
Philippe Girardon, Jean Amen, Versailles, France assigned to L'Air Liquide Societe Anonyme Pour l'Etude et l'Exploitation des Procedes Georges Claude A bacterial vaccine against Salmonella levers, typhoid and paratyphoid fevers is obtained by fermentation, extraction and purification, vaccinating membrane antigens being extracted by putting the bacterial residue, obtained by centrifuging, in contact with a solvent of the tris (hydroxyalkyl) aminoalkane class, with stirring, at lowered temperature, pH adjusted between 8.4 and 8.6 for a period of at least some 60 hours, then, separated by decanting, followed by purifying the antigens and fractionating by ultrafiltration, and then freeze-drying the vaccinating antigen fraction. Such vaccinating antigen fraction has a molecular weight greater than 50,000, preferably 300,000, and is used to vaccinate humans and animals.
A coagulant plasma-protein solution obtained by adsorbing stabilized human plasma at least once with 20-40 mg of colloidal silicic acid per gram of plasma protein and separating the adsorbent from the adsorbate, a method of manufacturing the solution, and a pharmaceutical preparation containing the solution and intended for the intravenous treatment of complex disorders of the hemostatic system. The solution is low in fibrinogen and factors X1 and XII but otherwise close in composition to the starting material.
4503155 MULTIFUNCTIONAL, CLONING VECTORS FOR USE IN STREPTOMYCES, BACILLUS, A N D E. C O L I James Miller, Jeffrey T Fayerman, Steven Kovacevic, Nancy E Beerman assigned to Eli Lilly and Company ~
lind Fun~'~onal Map
of Plssmld pLR2
4503038 EXTRACELLULAR NONMITOGENIC ANGIOGENESIS FACTOR AND METHOD OF ISOLATION THEREOF FROM WOUND FLUID Michael J Banda, Zena Werb, David R Knighton, Thomas K Hunt assigned to The Regents of the University of California A nonmitogenic angiogenesis factor is isolated from wound fluid by dialysis to include materials in the molecular size range of 2,000 to 14, 000, lyophilization, and chromatography. The nonmitogenic angiogenesis factor is identified by activity by corneal implant assay and by cell migration assay. The angiogenesis factor is also characterized by inactivity by mitogenesis assay.
~mm
The present invention discloses multifunctional recombinant DNA cloning vectors for use in Streptomyces, Bacillus, and E. coll. The invention further discloses transformants of the aforementioned vectors.
4504413 ACETAMINOPHEN ANALOGS, ANTIGENS, AND ANTIBODIES Pyar Khanna assigned to Syva Company
PATENT ABSTRACTS
preparative scale to provide homogeneous end product in excellent yield. In an embodiment of the process, human interferon is produced as a homogeneous protein.
4503039 COAGULANT PLASMA-PROTEIN SOLUTION Ronald Kotitschke, Wolfgang Stephan, Dreieich, Federal Republic Of Germany assigned to Biotest-Serum-lnstitut GmbH
4503036 PROCESS FOR PRODUCING BIOCHEMICAL VACCINE AGAINST SALMONELLA INFECTION
A
Philippe Girardon, Jean Amen, Versailles, France assigned to L'Air Liquide Societe Anonyme Pour l'Etude et l'Exploitation des Procedes Georges Claude A bacterial vaccine against Salmonella levers, typhoid and paratyphoid fevers is obtained by fermentation, extraction and purification, vaccinating membrane antigens being extracted by putting the bacterial residue, obtained by centrifuging, in contact with a solvent of the tris (hydroxyalkyl) aminoalkane class, with stirring, at lowered temperature, pH adjusted between 8.4 and 8.6 for a period of at least some 60 hours, then, separated by decanting, followed by purifying the antigens and fractionating by ultrafiltration, and then freeze-drying the vaccinating antigen fraction. Such vaccinating antigen fraction has a molecular weight greater than 50,000, preferably 300,000, and is used to vaccinate humans and animals.
A coagulant plasma-protein solution obtained by adsorbing stabilized human plasma at least once with 20-40 mg of colloidal silicic acid per gram of plasma protein and separating the adsorbent from the adsorbate, a method of manufacturing the solution, and a pharmaceutical preparation containing the solution and intended for the intravenous treatment of complex disorders of the hemostatic system. The solution is low in fibrinogen and factors X1 and XII but otherwise close in composition to the starting material.
4503155 MULTIFUNCTIONAL, CLONING VECTORS FOR USE IN STREPTOMYCES, BACILLUS, A N D E. C O L I James Miller, Jeffrey T Fayerman, Steven Kovacevic, Nancy E Beerman assigned to Eli Lilly and Company ~
lind Fun~'~onal Map
of Plssmld pLR2
4503038 EXTRACELLULAR NONMITOGENIC ANGIOGENESIS FACTOR AND METHOD OF ISOLATION THEREOF FROM WOUND FLUID Michael J Banda, Zena Werb, David R Knighton, Thomas K Hunt assigned to The Regents of the University of California A nonmitogenic angiogenesis factor is isolated from wound fluid by dialysis to include materials in the molecular size range of 2,000 to 14, 000, lyophilization, and chromatography. The nonmitogenic angiogenesis factor is identified by activity by corneal implant assay and by cell migration assay. The angiogenesis factor is also characterized by inactivity by mitogenesis assay.
~mm
The present invention discloses multifunctional recombinant DNA cloning vectors for use in Streptomyces, Bacillus, and E. coll. The invention further discloses transformants of the aforementioned vectors.
4504413 ACETAMINOPHEN ANALOGS, ANTIGENS, AND ANTIBODIES Pyar Khanna assigned to Syva Company